Clinical Pharmacology

Doctor-supervised pharmacological interventions: off-label rapamycin, GLP-1s, HRT/TRT, senolytics, low-dose tadalafil, and the metformin/TAME frame. Each entry names regulatory status, published-trial reference dose at the order-of-magnitude level, and explicit non-candidate populations.

Start with Rapamycin Off-Label Longevity Dosing: the section’s cleanest test of how to separate animal geroscience, early human surrogate trials, off-label prescribing, monitoring, and public enthusiasm. Then read GLP-1 Receptor Agonists for Longevity-Adjacent Outcomes for the opposite evidence shape: strong human disease-outcome trials in selected metabolic-risk populations, but no healthy-adult lifespan claim. The adjacent entries compare metformin, HRT/BHRT, TRT, senolytics, and low-dose tadalafil by evidence tier, candidate group, regulatory status, and the claims they do not yet support.

Read straight through, or land on a specific entry and follow its outgoing links into the rest of the book.